Sponsors who submit a drug application containing real-world data should ensure that certain measures have been taken ahead of time so that US Food and Drug Administration bioresearch monitoring (BIMO) inspectors can timely review RWD source records without delaying a product’s user fee date.
Prior to data extraction from the RWD source, sponsors should obtain signed informed consent from patients, or institutional review board...